GlassScriptPhysician profile
Phu N Tran
NPI 1891089587
$32,188.35
in general payments reported to CMS, 2019-2025
59 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $396 · 2021: $2,446 · 2022: $2,945 · 2023: $3,801 · 2024: $7,745 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $9,996 · Travel and Lodging: $4,768 · Long Term Medical Supply Or Device Loan: $250 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,037.50 |
| Food and Beverage | $9,996.13 |
| Travel and Lodging | $4,768.21 |
| Long Term Medical Supply Or Device Loan | $249.99 |
| Education | $229.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $12,216.45 | 2020-2025 | Imfinzi, Calquence, Truqap |
| Karyopharm Therapeutics INC. | $3,320.71 | 2023-2025 | Xpovio |
| Novartis Pharmaceuticals Corporation | $2,150.78 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,803.44 | 2020-2025 | Ofev |
| Pfizer INC. | $1,514.52 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $912.33 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $770.34 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Incyte Corporation | $747.99 | 2022-2025 | Jakafi, Pemazyre, Monjuvi |
| Genzyme Corporation | $648.53 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $522.26 | 2021-2025 | Libtayo, Lynozyfic |
| Celgene Corporation | $494.00 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Glaxosmithkline, LLC. | $477.83 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Eisai INC. | $413.03 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $384.14 | 2021-2025 | Fruzaqla, Ninlaro, Iclusig |
| Seagen INC. | $350.76 | 2020-2023 | Adcetris, Padcev, Tukysa |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $346.44 | 2020-2025 | Jaypirca, Verzenio, Retevmo |
| Abbvie INC. | $342.39 | 2022-2025 | Venclexta |
| Genentech USA, INC. | $296.14 | 2021-2025 | Tecentriq, Venclexta, Polivy |
| Daiichi Sankyo INC. | $285.13 | 2021-2025 | Enhertu, Datroway |
| Astellas Pharma US INC | $277.84 | 2020-2025 | Xtandi, Vyloy, Padcev |
| Mirati Therapeutics, INC. | $276.15 | 2023-2024 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $260.21 | 2020-2025 | |
| Puma Biotechnology, INC. | $259.83 | 2021-2025 | |
| Beigene USA, INC. | $237.95 | 2022-2025 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $212.77 | 2024-2025 | Ultomiris |
| Sobi, INC | $205.29 | 2022-2025 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $184.12 | 2021-2024 | Zepzelca |
| Amgen INC. | $183.57 | 2020-2023 | Xgeva, Kyprolis, Nplate |
| Ipsen Biopharmaceuticals, INC | $180.79 | 2023-2025 | Onivyde, Somatuline Depot, Tazverik |
| Beone Medicines USA, INC. | $180.66 | 2025 | Brukinsa, Tevimbra |
| Array Biopharma INC | $177.60 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Aveo Pharmaceuticals, INC. | $163.70 | 2022-2024 | Fotivda |
| Medtronic, INC. | $135.84 | 2024 | Osteocool Rf Ablation System |
| Exelixis INC. | $134.44 | 2019-2024 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $133.94 | 2022-2025 | Opdivo |
| Gilead Sciences, INC. | $78.94 | 2021-2024 | |
| G1 Therapeutics, INC. | $74.64 | 2022-2023 | Cosela |
| Accord Healthcare, INC. | $60.28 | 2023-2025 | |
| Emd Serono, INC. | $56.38 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $48.84 | 2020-2021 | |
| Tempus Ai, INC | $41.08 | 2024-2025 | Xt Cdx |
| Tolmar, INC. | $37.64 | 2023-2025 | Rubraca, Eligard |
| Servier Pharmaceuticals LLC | $36.82 | 2025 | |
| Kite Pharma, INC. | $30.95 | 2023 | Yescarta |
| Acceleron Pharma, INC. | $30.94 | 2021 | |
| Kyowa Kirin, INC. | $28.19 | 2025 | |
| Dova Pharmaceuticals | $27.60 | 2021 | |
| Amneal Pharmaceuticals LLC | $25.38 | 2024 | Neupogen, Avastin, Neulasta |
| Pharmacosmos Therapeutics INC. | $25.04 | 2025 | Monoferric |
| Novocure INC. | $24.55 | 2024 | Optune |
| Geron Corporation | $24.44 | 2025 | Rytelo |
| Shield Therapeutics INC | $24.35 | 2025 | |
| Azurity Pharmaceuticals, INC. | $22.53 | 2024 | Vivimusta |
| Pharmaand Gmbh | $20.83 | 2025 | Rubraca |
| Caris Mpi, INC. | $20.19 | 2025 | Mi Cancer Seek |
| Sun Pharmaceutical Industries INC. | $17.65 | 2022 | |
| Taiho Oncology, INC. | $16.94 | 2023 | |
| Janssen Pharmaceuticals, INC | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phu Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.